{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T01:10:32Z","timestamp":1790471432570,"version":"4.1.0"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s40618-021-01618-0","type":"journal-article","created":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T13:03:14Z","timestamp":1624626194000},"page":"89-94","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Revisiting the AJCC staging system of adrenocortical carcinoma"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-2502","authenticated-orcid":false,"given":"O.","family":"Abdel-Rahman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,25]]},"reference":[{"issue":"2","key":"1618_CR1","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1210\/er.2013-1029","volume":"35","author":"T Else","year":"2014","unstructured":"Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM et al (2014) Adrenocortical carcinoma. Endocr Rev 35(2):282\u2013326","journal-title":"Endocr Rev"},{"issue":"12","key":"1618_CR2","doi-asserted-by":"publisher","first-page":"4551","DOI":"10.1210\/jc.2013-3020","volume":"98","author":"M Fassnacht","year":"2013","unstructured":"Fassnacht M, Kroiss M, Allolio B (2013) Update in adrenocortical carcinoma. J Clin Endocrinol Metab 98(12):4551\u20134564","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"1618_CR3","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht M, Dekkers OM, Else T, Baudin E, Berruti A, de Krijger R et al (2018) European society of endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European network for the study of adrenal tumors. Eur J Endocrinol 179(4):G1-g46","journal-title":"Eur J Endocrinol"},{"issue":"4\u20136","key":"1618_CR4","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1007\/s12672-019-00367-0","volume":"10","author":"DH Owen","year":"2019","unstructured":"Owen DH, Patel S, Wei L, Phay JE, Shirley LA, Kirschner LS et al (2019) Metastatic adrenocortical carcinoma: a single institutional experience. Horm Cancer 10(4\u20136):161\u2013167","journal-title":"Horm Cancer"},{"issue":"6","key":"1618_CR5","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s12672-011-0088-0","volume":"2","author":"M Papotti","year":"2011","unstructured":"Papotti M, Lib\u00e8 R, Duregon E, Volante M, Bertherat J, Tissier F (2011) The Weiss score and beyond\u2013histopathology for adrenocortical carcinoma. Horm Cancer 2(6):333\u2013340","journal-title":"Horm Cancer"},{"issue":"10","key":"1618_CR6","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","volume":"26","author":"R Lib\u00e9","year":"2015","unstructured":"Lib\u00e9 R, Borget I, Ronchi CL, Zaggia B, Kroiss M, Kerkhofs T et al (2015) Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European network for the study of adrenal tumor (ENSAT) study. Ann Oncol 26(10):2119\u20132125","journal-title":"Ann Oncol"},{"key":"1618_CR7","unstructured":"DeLellis RA (2004) Pathology and genetics of tumours of endocrine organs. IARC"},{"issue":"2","key":"1618_CR8","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1002\/cncr.24030","volume":"115","author":"M Fassnacht","year":"2009","unstructured":"Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F et al (2009) Limited prognostic value of the 2004 International Union against cancer staging classification for adrenocortical carcinoma. Cancer 115(2):243\u2013250","journal-title":"Cancer"},{"key":"1618_CR9","unstructured":"Amin MB, Edge SB (2017) AJCC cancer staging manual. Springer"},{"key":"1618_CR10","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (2020) SEER*Stat Database: incidence\u2014SEER research data, 18 registries, Nov 2019 sub (2000\u20132017)\u2014linked to county attributes\u2014time dependent (1990\u20132017) income\/rurality, 1969\u20132018 counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission. Available at: www.seer.cancer.gov. Accessed 24 Nov 2020"},{"issue":"11","key":"1618_CR11","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht M, Assie G, Baudin E, Eisenhofer G, de la Fouchardiere C, Haak HR et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(11):1476\u20131490","journal-title":"Ann Oncol"},{"issue":"4","key":"1618_CR12","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.path.2019.08.010","volume":"12","author":"A Vaidya","year":"2019","unstructured":"Vaidya A, Nehs M, Kilbridge K (2019) Treatment of adrenocortical carcinoma. Surg Pathol Clin 12(4):997\u20131006","journal-title":"Surg Pathol Clin"},{"issue":"2","key":"1618_CR13","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/1756287217737706","volume":"10","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman O (2018) Validation of American joint committee on cancer eighth staging system among prostate cancer patients treated with radical prostatectomy. Ther Adv Urol 10(2):35\u201342","journal-title":"Ther Adv Urol"},{"issue":"1","key":"1618_CR14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10549-017-4577-x","volume":"168","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman O (2018) Validation of the 8th AJCC prognostic staging system for breast cancer in a population-based setting. Breast Cancer Res Treat 168(1):269\u2013275","journal-title":"Breast Cancer Res Treat"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01618-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01618-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01618-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,7]],"date-time":"2022-01-07T19:15:56Z","timestamp":1641582956000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01618-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,25]]},"references-count":14,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1618"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01618-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,25]]},"assertion":[{"value":"13 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Advisory board; Eisai Canada, Lilly Canada, and Roche Canada.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As this study is based on a publicly available database without identifying patient information, informed consent was not needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}